(Q53720651)

English

Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

0 references

0 references

polycythemia vera

1 reference

based on heuristic

inferred from title

Cédric Cleyrat

2

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

author name string

M Boissinot

1

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

M Vilaine

3

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

Y Jacques

4

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

I Corre

5

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

S Hermouet

6

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

30

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

8

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

990-1001

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Drug development of MET inhibitors: targeting oncogene addiction and expedience

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Global cytokine analysis in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Genetic complexity of myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Soluble angiogenic factors: implications for chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Polycythemia vera is not initiated by JAK2V617F mutation.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Polycythemia vera megakaryocytes but not megakaryocytes from normal controls and patients with smokers polyglobuly spontaneously express IL-6 and IL-6R and secrete IL-6.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.479

31 March 2020

Identifiers

10.1038/ONC.2010.479

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 May 2018

http://europepmc.org/abstract/MED/21042281

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53720651&oldid=2212273484"